AG真人官方

Item 7.01 鈥� Regulation FD: On 30 Jul 2025 Moleculin Biotech, Inc. (NASDAQ: MBRX) furnished an 8-K announcing it has received a Notice of Intent to Grant for European patent application 鈥淧reparation of Pre-liposomal Annamycin Lyophilizate.鈥�

The disclosure, provided via attached Exhibit 99.1, indicates the patent is expected to cover the Company鈥檚 Annamycin formulation in Europe once formally issued. No financial statements, earnings data or other operational metrics are included. The information is expressly furnished, not filed, and therefore will not be incorporated into other Exchange Act or Securities Act reports unless later referenced. Exhibit 104 supplies the Inline XBRL cover page.

Steelcase, Inc. (NYSE:SCS) has filed a Form 144 indicating that insider Robert Krestakos intends to sell 12,000 common shares through Morgan Stanley Smith Barney on or about 11 July 2025. The planned sale is valued at roughly $127,546, a negligible 0.011% of the 114.7 million shares outstanding. These shares were acquired via performance and restricted stock awards granted between 2018 and 2021. Over the last three months the same insider sold an additional 6,000 shares for proceeds of approximately $61,000. No operational, earnings, or strategic disclosures accompany this filing, making it chiefly an administrative notice of modest insider selling.

Hudson Acquisition I Corp. (HUDAU) has filed a Form 25 with the U.S. Securities and Exchange Commission, initiated by Nasdaq Stock Market LLC, to remove the company鈥檚 common stock, rights and units from both listing on Nasdaq and registration under Section 12(b) of the Exchange Act (Commission File No. 333-264557).

The notice states that Nasdaq believes it satisfies all procedural requirements for filing and has certified this via an authorized signatory on 11 July 2025. Once the Form 25 becomes effective, the specified securities will no longer trade on the exchange, and the company will cease to be subject to related ongoing reporting obligations for those classes unless other Exchange Act sections apply.

Investors should understand that a Form 25 generally leads to the termination of exchange trading and may reduce liquidity and price transparency for the affected securities. No financial results, business rationale or forward-looking statements were provided in the filing.

On July 9, 2025, Moleculin Biotech, Inc. (NASDAQ: MBRX) filed an 8-K to disclose a material regulatory milestone. The filing states that the Regulation Agency for Medical and Pharmaceutical Activities (RAMPA) of Georgia has approved the company鈥檚 Clinical Trial Application (CTA) for a pivotal Phase 2B/3, multi-center, randomized, double-blind, placebo-controlled, adaptive-design study evaluating Annamycin in combination with cytarabine ("AnnAraC") in adult patients with relapsed or refractory acute myeloid leukemia (R/R AML).

This authorization allows Moleculin to initiate a late-stage trial that could serve as a registration study if successful, marking a critical progression from earlier trial phases. The company furnished the related press release as Exhibit 99.1; the information is deemed "furnished" rather than "filed," meaning it is not automatically incorporated into other Securities Act or Exchange Act filings.

No financial metrics, earnings data, or transaction details accompany the disclosure. The filing is limited to the regulatory update and requisite Exhibit list, signalling a strategic but non-financially quantified milestone for the firm鈥檚 oncology pipeline.

JPMorgan Chase Financial Company LLC, fully guaranteed by JPMorgan Chase & Co., is offering Trigger Callable Yield Notes that mature on or about 14 October 2026 and are linked to the lesser-performing of the Russell 2000庐 Index (RTY) and the EURO STOXX 50庐 Index (SX5E).

Key economic terms

• Issue price: $10 per Note; minimum investment $1,000 (100 Notes).
• Term: 15 months, unless called earlier.
• Coupon rate: expected 7.50 % 鈥� 8.15 % p.a., paid monthly ($0.0625 鈥� $0.0679 per $10 principal); coupons paid regardless of index performance while Notes remain outstanding.
• Call feature: after an initial three-month non-call period, issuer may call on any monthly Optional Call Notice Date (beginning 9 Oct 2025). If called, payment equals principal + current coupon; no further coupons.
• Downside protection: contingent only. If not called and the Final Value of each index 鈮� 70 % of its Initial Value (Downside Threshold), principal is repaid in full plus final coupon. If either index closes below its threshold, repayment equals $10 脳 (1 + Lesser Performing Underlying Return) + final coupon, so investors lose 1 % of principal for every 1 % decline below the Initial Value and could lose their entire investment.
• Estimated value: on pricing date will be 鈮� $9.50 (illustrative value if priced on 7 Jul 2025: $9.801) per $10 Note, lower than issue price because of selling commissions (鈮� $0.10) and hedging costs.
• Secondary market: Notes will not be listed; J.P. Morgan Securities LLC intends, but is not obliged, to make markets.
• Credit exposure: payments depend on the credit of JPMorgan Financial and JPMorgan Chase & Co.; Notes are unsecured and unsubordinated.
• Key dates: Trade Date 9 Jul 2025; Settlement 14 Jul 2025; Final Valuation Date 9 Oct 2026 (subject to adjustments); Maturity 14 Oct 2026.

Illustrative outcomes

• Early call (first possible in Oct 2025): investors receive roughly $10.06 plus prior coupons鈥攖otal return about 1.9 % over three months.
• Not called; both indices above threshold: total coupons (~$0.9375) + principal for ~9.4 % total return over 15 months.
• Not called; one index down 60 %: investor receives only $4.00 principal + coupons for a 鈥�50.6 % total return.

Principal risks highlighted

• Full downside exposure to the lower-performing index if it breaches the 70 % threshold.
• Issuer call risk limits total coupon potential and may force reinvestment at lower rates.
• Credit risk of both JPMorgan Financial and the parent guarantor.
• Complex tax treatment; Notes intended to be treated as a unit comprising a put option and a deposit.
• Lack of liquidity; secondary prices expected to be below issue price and influenced by issuer鈥檚 internal funding rate.

The pricing supplement emphasises that the Notes are 鈥渟ignificantly riskier than conventional debt instruments鈥� and warns that investors should be prepared to lose a substantial portion or all of their principal.

Moleculin Biotech (MBRX) has announced a significant public offering totaling $5.9 million in gross proceeds, with potential for an additional $17.8 million if all warrants are exercised. The offering, which closed on June 23, 2025, includes:

• 9,972,026 shares of common stock
• 6,107,974 pre-funded warrants at $0.001 exercise price
• 48,240,000 Series E warrants at $0.37 initial exercise price

Notable aspects include insider participation, with CEO Walter Klemp and CFO Jonathan Foster purchasing 1,027,026 shares and 3,081,078 warrants. Roth Capital Partners served as placement agent, receiving a 7% fee. The proceeds will fund clinical development of Annamycin and two other drug portfolios, preclinical studies, and working capital.

The offering includes significant stockholder approval requirements and anti-dilution provisions, with warrant exercise prices subject to potential downward adjustments (floor price $0.12). The company has agreed to a 60-day restriction on new share issuances following stockholder approvals.

Jonathan P. Foster, Chief Financial Officer of Moleculin Biotech (MBRX), reported multiple securities transactions on June 20-23, 2025:

• Acquired 2,711 shares from RSUs and had 661 shares withheld for taxes on June 20
• Acquired 4,328 shares from RSUs and had 1,054 shares withheld for taxes on June 22
• Purchased 270,270 common shares at $0.37 per share in a public offering on June 23
• Acquired Series E warrants to purchase 810,810 shares at $0.37/share, exercisable upon stockholder approval with 5-year expiration

Following these transactions, Foster directly owns 287,587 common shares and 1,038,320 derivative securities. The RSUs were granted in 2022 (10,846 units) and 2023 (17,313 units), vesting in four annual installments. This significant insider purchase demonstrates management's confidence in the company's prospects.